Business Context and Reporting Period
Company: Protagonist Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 3, 2019
Reporting Period: Event date of December 3, 2019
Business Context: The Company is an emerging growth company focused on developing hepcidin mimetics. This filing reports the announcement of preliminary Phase 2 clinical trial results for its lead candidate, PTG-300, in the treatment of transfusion-dependent beta-thalassemia.
Key Financial Metrics
This Form 8-K is an event-driven report and does not contain audited financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes
The material event reported is the release of preliminary Phase 2 clinical data for PTG-300. There are no reported changes to financial position, capital structure, or operations other than the clinical milestone achievement.
Guidance, Outlook, and Management Commentary
- Clinical Update: The Company announced preliminary Phase 2 results with hepcidin mimetic PTG-300 for transfusion-dependent beta-thalassemia.
- Management Action: A conference call was scheduled for December 3, 2019, at 8:30 a.m. Eastern Time to discuss the preliminary results.
- Exhibits: The full press release detailing the results is attached as Exhibit 99.1.
- Risks and Contingencies: No specific risks or contingencies are detailed in the body of this 8-K, though clinical trial results inherently carry development risks.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) for specific efficacy and safety data points regarding PTG-300.
- Verify the transcript or recording of the December 3, 2019, conference call for management's detailed interpretation of the results.
- Check subsequent filings (e.g., 10-Q or 10-K) for the impact of these results on the Company's cash burn rate and future funding needs.
- Confirm the regulatory status of the Phase 2 trial and any planned next steps (e.g., Phase 3 initiation) mentioned in the press release.